A retrospective cohort study investigated the real-world effectiveness and safety of olaparib, a PARP inhibitor, in patients with newly diagnosed advanced-stage, high-grade serous ovarian cancer ...

PARP-1 is an enzyme directly involved in repairing ... like [BRCA1/2 or] triple-negative breast cancer,” says Winer. AstraZeneca's olaparib isn't being tested in TNBC but in people with ...

However, the approaches within these trials resemble the Olaparib trials ... to be published. Table 1. Poly-(ADP-ribose) polymerase inhibitors in clinical studies. PARP inhibitor Number of ...

If people with the condition and their healthcare professional, after discussing the advantages and disadvantages of all the options, consider olaparib to be 1 of a range of suitable treatments, the ...

AstraZeneca’s Lynparza (olaparib) blazed a trail for the ... which would really broaden the use of PARP inhibitors.” The phase 1 PETRA trial of AZD5305 has already begun in solid tumours ...

“Effectively, in the PAOLA-1 trial we reported three years ago the benefit of using olaparib and bevacizumab ... used as a biomarker for administering PARP inhibitors or platinum-based ...

Table 1. Poly-(ADP-ribose) polymerase inhibitors in clinical studies. PARP inhibitor Number of completed ... were studied Combination therapy studied Olaparib (AZD2281) 52 Phase I, II and III ...